华润双鹤：子公司获得注射用替加环素药品注册证书

Core Viewpoint - China Resources Double Crane (华润双鹤) announced that its wholly-owned subsidiary, Double Crane Pharmaceutical (Hainan) Co., Ltd., has received a drug registration certificate from the National Medical Products Administration for injectable Tigecycline. This drug is clinically used to treat complex skin and soft tissue infections and complicated intra-abdominal infections caused by sensitive bacteria [1] Group 1 - The research and development for the generic version of injectable Tigecycline was initiated in December 2021, with a total R&D investment of 10.27 million yuan (1,027.05 thousand) as of the announcement date [1] - The global sales of injectable Tigecycline reached 218 million USD in 2023, while the total sales in the domestic market amounted to 848 million yuan [1]